Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17825271 | 1.00 | PARG (1.00) | PARG | |
| SCHEMBL17824828 | 0.91 | PARG (1.00) | PARG | |
| SCHEMBL17824685 | 0.87 | PARG (1.00) | PARG | |
| SCHEMBL17825352 | 0.86 | PARG (1.00) | PARG | |
| SCHEMBL19770727 | 0.86 | PARG (1.00) | PARG | |
| SCHEMBL17824833 | 0.86 | PARG (1.00) | PARG | |
| SCHEMBL24570171 | 0.85 | PARG (0.74) | PARG | |
| SCHEMBL31072665 | 0.85 | PARG (1.00) | PARG | |
| SCHEMBL19770734 | 0.85 | PARG (1.00) | PARG | |
| SCHEMBL17824866 | 0.84 | PARG (1.00) | PARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025233535-A1 | METHOD FOR THE DETERMINATION OF CLEAVAGE SITES IN GENOMIC DNA CAUSED BY EXPOSURE TO A SITE DIRECTED NUCLEASE | ETH Zürich (CH) | 2025-11-13 | — | — | WO | claimed |
| US-20250255881-A1 | Cancer Treatment | UNIV OF SOUTH ALABAMA FOUNDATION FOR RESEARCH AND COMMERCIALIZATION (US) | 2025-08-14 | — | — | US | claimed |
| CN-119033940-A | Use of PAR hydrolase inhibitors (PDD) for the treatment of peripheral neuropathies associated with DNA damage | 中南大学 | 2024-11-29 | — | — | CN | claimed |
| WO-2024186926-A1 | STRATEGIES TO PREVENT THE EVOLUTION OF LETHAL, MULTI-THERAPY-RESISTANT, WIDELY METASTATIC CUTANEOUS MELANOMA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-12 | — | — | WO | claimed |
| US-20240285647-A1 | Cancer Treatment | CANAL HOUSE BIOSCIENCES, LLC | 2024-08-29 | — | — | US | claimed |
| EP-4401721-A1 | CANCER TREATMENT | University of South Alabama Foundation For Research and Commercialization (US) | 2024-07-24 | — | — | EP | claimed |
| WO-2024081789-A2 | HISTONE DEMETHYLASE INHIBITORS FOR TREATING CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-18 | — | — | WO | claimed |
| WO-2023064619-A1 | CANCER TREATMENT | University of South Alabama Foundation for Research and Commercialization (US) | 2023-04-20 | — | — | WO | claimed |
| CN-122071469-A | PARG inhibitor and preparation method and application thereof | 烟台新药创制山东省实验室 | 2026-05-22 | — | — | CN | disclosed |
| US-20260132140-A1 | IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| CN-121971629-A | Pharmaceutical composition for combined administration of JNK inhibitor and PARG inhibitor and pharmaceutical application | 中国科学院杭州医学研究所 | 2026-05-05 | — | — | CN | disclosed |
| US-12601734-B2 | Methods and uses of enzymatic labeling of ADP-ribose containing molecules | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-04-14 | — | — | US | disclosed |
| EP-3947351-B1 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF | UNIV TEXAS (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260049088-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| WO-2022245922-A1 | POLY-ADP RIBOSE (PAR) TRACKER OPTIMIZED SPLIT-PROTEIN REASSEMBLY PAR DETECTION REAGENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-11-24 | — | — | WO | disclosed |
| US-20220202821-A1 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220098196-A1 | TRAPPING-FREE PARP INHIBITORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2022060477-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220050112-A1 | FLUORESCENT SUBSTRATES FOR POLY(ADP-RIBOSYL) HYDROLASES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3947351-A2 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF | Board of Regents, The University of Texas System (US) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132140-A1 | IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS | CHEK1, CHEK2, BUB1 | PARG 4306/4885 |
| US-20220202821-A1 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF | PARG, PARP15, PLG | PARG 1/4885 |
| US-20220098196-A1 | TRAPPING-FREE PARP INHIBITORS | PARP1, PARP3, PARP11 | PARG 133/4885 |
| US-12601734-B2 | Methods and uses of enzymatic labeling of ADP-ribose containing molecules | PARP15, PARP12, PARP11 | PARG 44/4885 |
| US-20260049088-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | SRD5A2, CBR1, SRD5A1 | PARG 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.